Explore a selection of our essential drug information below, or:
Identification
- Summary
Obiltoxaximab is a monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
- Brand Names
- Anthim
- Generic Name
- Obiltoxaximab
- DrugBank Accession Number
- DB05336
- Background
Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- 148000.0 Da
- Sequences
- Not Available
- Synonyms
- Obiltoxaximab
- External IDs
- ETI-204
Pharmacology
- Indication
Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Inhalational anthrax •••••••••••• Prophylaxis of Inhalational anthrax •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Obiltoxaximab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Obiltoxaximab. Aducanumab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab. Alirocumab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Alirocumab. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Anthim Solution 100 mg / mL Intravenous Elusys Therapeutics, Inc. 2022-09-13 Not applicable Canada 
Anthim Solution 100 mg/1mL Intravenous Elusys Therapeutics, Inc. 2016-03-18 Not applicable US 
Obiltoxaximab Sfl Injection, solution, concentrate 100 mg/ml Intravenous Sfl Pharmaceuticals Deutschland Gmb H 2020-12-23 2020-09-17 EU 
Categories
- ATC Codes
- J06BC04 — Obiltoxaximab
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Anthrax Protective Antigen-directed Antibody
- Anthrax Protective Antigen-directed Antibody Interactions
- Antibacterial monoclonal antibodies
- Antibodies
- Antiinfectives for Systemic Use
- Biological Products
- Blood Proteins
- Body Fluids
- Complex Mixtures
- Globulins
- Immune Sera
- Immune Sera and Immunoglobulins
- Immunoglobulins
- Immunoproteins
- Proteins
- Serum Globulins
- Specific Immunoglobulins
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 29Z5DNL48C
- CAS number
- 1351337-07-9
References
- General References
- Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun. 2005 Feb;73(2):795-802. [Article]
- External Links
- PubChem Substance
- 347910089
- 1746906
- Wikipedia
- Obiltoxaximab
- FDA label
- Download (315 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Not Yet Recruiting Treatment Anthrax / Bacterial Infections 1 somestatus stop reason just information to hide 1 Completed Other Inhalational Anthrax 4 somestatus stop reason just information to hide 1 Completed Treatment Anthrax 1 somestatus stop reason just information to hide 1 Completed Treatment Bacillus Anthracis (Anthrax) 1 somestatus stop reason just information to hide 1 Completed Treatment Healthy Volunteers (HV) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 100 mg / mL Solution Intravenous 100 mg/1mL Injection, solution, concentrate Intravenous 100 MG/ML - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at November 18, 2007 18:23 / Updated at April 30, 2021 13:06